Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 21,07 € (+32,10 %). La mediana es de 18,63 € (+16,80 %).
| Comprar |
23 |
| Mantener |
16 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Tandem Diabetes relies on pharmacy model, Mobi‑Patch and international direct sales for growth
Tandem Diabetes unveiled a long-term growth plan that includes a pharmacy-based pay-as-you-go model in the US, broader rollout of the tubeless Mobi‑Patch pump in the second half of 2026, and expansion of direct sales activities in selected international markets. The new US model is intended to remove the initial cost barrier for patients and bring up to 80% of US sales through pharmacies; internationally, the company expects higher prices and better follow-on care via direct business. New patient starts stalled in the second quarter, but Tandem expects growth in the second half of the year driven by product dynamics, seasonal demand and additional PBM coverage. At the same time, the company is advancing automation projects, including development toward a fully closed‑loop insulin system and integration of existing CGM technologies. » Más en de.investing.com
Tandem Diabetes Care beats profit forecasts, shares fall after slight revenue miss
Tandem Diabetes Care reported adjusted EPS of -$0.31 for Q2, beating the analyst estimate of -$0.33, while revenue of $254.6 million missed estimates only slightly. Gross margin rose to 57% and adjusted EBITDA margin reached 3%, marking the fourth consecutive positive quarter. Management reaffirmed the full-year outlook, highlighted record shipments and progress in pharmacy distribution, and expects approval of Mobi Tubeless in the second half of 2026. The stock fell about 4.1% in regular trading and recovered slightly in after-hours trading. » Más en de.investing.com
Tandem Diabetes Care lags after reimbursement shift clouds near-term revenue
Meridian Small Cap Growth Fund said Tandem Diabetes Care underperformed in Q2 as its transition to a pharmacy-based, pay-as-you-go reimbursement model reduced near-term revenue visibility and second-quarter guidance missed expectations. The fund noted added caution from a new competing patch-pump entrant and that Tandem’s lower-beta profile lagged in a market favoring high-beta names. Meridian remains invested, citing the company’s differentiated pump technology, growing installed base and recurring supply revenue, and views the reimbursement change as a long-term positive. » Más en finance.yahoo.com
Tandem Diabetes receives CE marking for expanded pump indications in Europe
Tandem Diabetes has received CE approval in Europe for its automated insulin delivery systems t:slim X2 and Tandem Mobi with Control‑IQ+ for use in pregnant people with Type 1 diabetes and in adults with Type 2 diabetes. The stock rose nearly 8% on the news and the company posted a weekly gain of 13%; market capitalization about $1.33 billion. The approval is based on the CIRCUIT study (improved time in range for pregnant people) and the 2IQP study (HbA1c reductions in Type 2 diabetes). The t:slim X2 is already available in several countries; Tandem Mobi is slated for H2 2026 launch. Analysts do not expect the company to be profitable this year. » Más en de.investing.com
Tandem Diabetes Care reports record revenue for Q1 2026, stock falls sharply
Tandem Diabetes Care posted record revenue of $247.22 million in Q1 2026 and beat expectations with an EPS of -0.30 versus -0.44 expected. Gross margin improved to 55% and operating margin to -7%, and free cash flow of $5 million was generated. Despite the positive metrics, the stock fell about 14% in after-hours trading; the company plans product launches and international expansion in the second quarter. Management cites the integration of FreeStyle Libre 3 Plus and the international rollout of Tandem Mobi as growth drivers. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 250,46 M | 17,92 % |
| Beneficio bruto | 141,63 M | 23,76 % |
| Beneficio neto | -6,25 M | 65,32 % |
| EBITDA | -772,49 mil | 95,12 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1272,94 M € |
Número de acciones | 69,79 M |
Máximo/mínimo de 52 semanas | 26,94 € - 11,14 € |
| Dividendos | No |
Beta | 1,60 |
Ratio P/E | -27,93 |
Ratio PEG | -0,18 |
Ratio P/B | 10,35 |
Ratio P/S | 1,30 |
Perfil de la empresa
Tandem Diabetes Care, Inc., una empresa de dispositivos médicos, diseña, desarrolla y comercializa diversos productos para personas con diabetes dependiente de insulina en Estados Unidos y a nivel internacional. El producto insignia de la compañía es el sistema de administración de insulina t:slim X2, una plataforma de bomba que comprende la bomba t:slim X2, su cartucho desechable de insulina de 300 unidades y un equipo de infusión. También ofrece t:slim X2 con insulina Basal-IQ y tecnología Control-IQ; t:slim X2 con integración G5; y Tandem Device Updater, una herramienta que permite a los usuarios actualizar el software de su bomba. Además, la compañía ofrece t:connect, una aplicación web de gestión de datos que proporciona una forma visual de mostrar los datos de gestión de la terapia de diabetes procedentes de la bomba, la monitorización continua de glucosa y los glucómetros compatibles para los usuarios, sus cuidadores y sus proveedores de atención médica; y Sugarmate, una aplicación móvil para personas con diabetes que usan insulina. La empresa tiene acuerdos de desarrollo y comercialización con Dexcom, Inc. y Abbott Laboratories. Anteriormente, la compañía se conocía como Phluid Inc. y cambió su nombre a Tandem Diabetes Care, Inc. en enero de 2008. Tandem Diabetes Care, Inc. se constituyó en 2006 y tiene su sede en San Diego, California.
| Nombre | Tandem Diabetes Care |
| CEO | John F. Sheridan |
| Sede | San Diego,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 14/11/2013 |
| Empleados | 2500 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | TNDM |
Frankfurt | TD5A.F |
Düsseldorf | TD5A.DU |
London | 0M0F.L |
München | TD5A.MU |